Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

S.E. Bowyer, A.D. Rao, M. Lyle, S. Sandhu, G. Long, G.A. Mcarthur, J.M. Raleigh, R.J. Hicks, Michael Millward

    Research output: Contribution to journalArticlepeer-review

    62 Citations (Web of Science)


    © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation. Paired biopsies available in one of the five patients showed reduced phospho-ERK signalling and this corresponded to a metabolic response on 18F-fluorodeoxyglucose-PET scanning. Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.
    Original languageEnglish
    Pages (from-to)504-508
    JournalMelanoma Research
    Issue number5
    Publication statusPublished - 2014


    Dive into the research topics of 'Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma'. Together they form a unique fingerprint.

    Cite this